ReviewFrontiers in cellular and infection microbiology2012
Leishmania RNA virus: when the host pays the toll.
Review in Frontiers in cellular and infection microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.
- The prevalence of Leishmania RNA virus in cutaneous leishmaniasis: a meta-analysis and systematic review.BMC infectious diseases · 2025Pooled it
- Pooled it
- Review
- Article
- First report of Leishmania RNA virus 2 and its high genetic diversity in cutaneous leishmaniasis cases from Ilam Province, Iran.BMC medical genomics · 2025Article
- The expression profile of inflammatory microRNAs in Leishmania major infected human macrophages; mining the effects of Leishmania RNA virus.BMC microbiology · 2025Article
- Exploring the significant genetic diversity of Iranian isolates of Leishmania RNA virus 2 using whole genome sequence analysis.BMC infectious diseases · 2024Article
- Case Report: A Case of Sporotrichoid Cutaneous Leishmaniasis Caused by Leishmania (Viannia) peruviana.The American journal of tropical medicine and hygiene · 2024Article
- Microbial Matryoshka: Addressing the Relationship between Pathogenic Flagellated Protozoans and Their RNA Viral Endosymbionts (FamilyVeterinary sciences · 2024Review
- Proteome profiling of cutaneous leishmaniasis lesions due to dermotropic Leishmania donovani in Sri Lanka.Clinical proteomics · 2024Article
- Visceral Leishmaniasis in a Twin Pregnancy: A Case Report and Review of the Literature.Journal of clinical medicine · 2024Review
- Immunization withVaccines · 2024Article
- Novel detection ofParasitology · 2024Article
- Proteome profiling of cutaneous leishmaniasis lesions due to dermotropicbioRxiv : the preprint server for biology · 2024Article
- Live attenuated-nonpathogenicFrontiers in microbiology · 2024Review
- Diversity and dissemination of viruses in pathogenic protozoa.Nature communications · 2023Article
- The effects of Leishmania RNA virus 2 (LRV2) on the virulence factors of L. major and pro-inflammatory biomarkers: an in vitro study on human monocyte cell line (THP-1).BMC microbiology · 2023Article
- Exploring Host-Specificity: Untangling the Relationship betweenMicroorganisms · 2023Article
- Systematic Review of Treatment Failure and Clinical Relapses in Leishmaniasis from a Multifactorial Perspective: Clinical Aspects, Factors Associated with the Parasite and Host.Tropical medicine and infectious disease · 2023Review
- Cryptosporidium uses CSpV1 to activate host type I interferon and attenuate antiparasitic defenses.Nature communications · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The presence of an RNA virus in a South American subgenus of the Leishmania parasite, L. (Viannia), was detected several decades ago but its role in leishmanial virulence and metastasis was only recently described. In Leishmania guyanensis, the nucleic acid of Leishmania RNA virus (LRV1) acts as a potent innate immunogen, eliciting a hyper-inflammatory immune response through toll-like receptor 3 (TLR3). The resultant inflammatory cascade has been shown to increase disease severity, parasite persistence, and perhaps even resistance to anti-leishmanial drugs. Curiously, LRVs were found mostly in clinical isolates prone to infectious metastasis in both their human source and experimental animal model, suggesting an association between the viral hyperpathogen and metastatic complications such as mucocutaneous leishmaniasis (MCL). MCL presents as chronic secondary lesions in the mucosa of the mouth and nose, debilitatingly inflamed and notoriously refractory to treatment. Immunologically, this outcome has many of the same hallmarks associated with the reaction to LRV: production of type 1 interferons, bias toward a chronic Th1 inflammatory state and an impaired ability of host cells to eliminate parasites through oxidative stress. More intriguing, is that the risk of developing MCL is found almost exclusively in infections of the L. (Viannia) subtype, further indication that leishmanial metastasis is caused, at least in part, by a parasitic component. LRV present in this subgenus may contribute to the destructive inflammation of metastatic disease either by acting in concert with other intrinsic "metastatic factors" or by independently preying on host TLR3 hypersensitivity. Because LRV amplifies parasite virulence, its presence may provide a unique target for diagnostic and clinical intervention of metastatic leishmaniasis. Taking examples from other members of the Totiviridae virus family, this paper reviews the benefits and costs of endosymbiosis, specifically for the maintenance of LRV infection in Leishmania parasites, which is often at the expense of its human host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.